Evidence. Value. Access. Everything you need to demonstrate patient outcomes and make a clear value case to decision-makers with speed and confidence.
.avif)
Pharmaceutical companies face one of the toughest environments in healthcare today. Market access means achieving payer approval, aligning pricing strategies, demonstrating cost effectiveness, and proving health outcomes across diverse healthcare systems.
That’s why Alkemi helps you tackle the toughest challenges head-on with…
Clear value stories and robust evidence planning
Plans to bring rare disease treatments to patients faster
Assistance during complex pricing and reimbursement negotiations
With the right plan, you can turn obstacles into opportunities that strengthen your position and achieve lasting commercial success.
Pharmaceutical companies face one of the toughest environments in healthcare today. Market access means achieving payer approval, aligning pricing strategies, demonstrating cost effectiveness, and proving health outcomes across diverse healthcare systems.
That’s why Alkemi helps you tackle the toughest challenges head-on with…
Major change in clinical practice or care delivery required
Treatment isn't favorably positioned in clinical guidelines
Low market awareness of unmet need
Treatment is expensive and it's unclear why payers should cover it
Policy is supportive of status quo (which doesn't include your treatment)
With the right plan, you can turn obstacles into opportunities that strengthen your position and achieve lasting commercial success.
Alkemi partners with pharmaceutical companies to design and implement effective market access and HEOR strategies across the drug development life cycle. From early stages of clinical development to post-launch defense, we help you anticipate market access challenges and build a comprehensive evidence and market access strategy tailored to your asset.
Whether you’re:
Approaching launch and building the evidence base for rapid access
Preparing coordinated access strategies across major markets
Navigating payer processes and price negotiations
Addressing EU joint clinical assessment requirements
When your treatment is under pressure, you need a plan fast. Alkemi’s Access Threat Response System™ helps you realign teams, rebuild confidence with payers, and deploy a launch-ready strategy in 90 days or less.
Starting at
$150k
When your product is already under pressure, you need a plan fast. Alkemi’s Access Threat Response System™ helps you realign teams, rebuild confidence with payers, and deploy a launch-ready strategy in 90 days or less.
Starting at
$100k
We translate clinical trial data and real world evidence into health economics and outcomes research that speaks to payers and regulatory bodies. This evidence package strengthens global value dossiers to achieve positive HTA and pricing decisions.
Our team builds clear, actionable market access and HEOR plans — not just slide decks. These include evidence generation, economic modeling, guidelines positioning, stakeholder engagement, launch sequence and pricing plans designed to achieve market access and secure broad adoption.
From the early stages of drug development through commercialization, Alkemi equips your HEOR and market access teams with the tools and frameworks to address access barriers, anticipate market dynamics, and adapt pricing strategies in real time.
Pharmaceutical companies need to expand and defend market share, demonstrate patient outcomes, and make a clear value case to decision makers, so you can reach patients while helping your organization thrive.
Pharma leaders call Alkemi when the clock is ticking and the stakes are high.
Our team has guided 50+ treatments to global success, including some of the toughest rare disease launches.
Our consultants are capable of ensuring payer coverage within the first week of launch. We build 90-day access strategies that get scattered teams aligned and decision-makers on board.
But what clients value most isn’t just our speed, but our depth.
They’ve come to us after vendors handed them generic slides, when leadership needed confidence before a board meeting, or when silos made it impossible to act.
We help them uncover the insights that matter and deliver a plan leadership can use the same day, not months later.
That’s why commercial leaders trust Alkemi.
Because when everything is on the line, they know we don’t hand over theory. We deliver clarity, alignment, and a plan that actually works in practice.
"The workshop went flawlessly - thanks so much for making sure that everything (logistics, facilitation, etc) ran smoothly."
"There were no airs and graces… with some agencies you get a really young associate transcribing, then multiple layers of people. With them, it was just two people to get things done."
"Thanks to the whole team involved in staging this Advisory Council. I was fortunate to be able to attend and here the insights from the council members firsthand. The report provides an excellent summary."
"Thanks for sharing the final materials! Many thanks to you and the rest of the Alkemi team for a success project. We really appreciated the excellent collaboration and quality work. It’s been a pleasure working with all of you on this project! Looking forward to the next one…"
“Their strategic insights and support were essential – they have a knack for communicating differentiated value.”
![image of successful businesses [headshot]](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c59ad68004ea9ddd6b4_c1cd2a51-1f06-45cb-9a13-4199a77f0015.avif)
“They helped us identify our evidence gaps and develop a solid communication tool aligned with stakeholder needs. And they’re fun to work with!”
![[headshot]](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c59dcf34a6442165770_122204b6-f407-479f-9bb7-84c323ad8f65.avif)
“Excellent work! Alkemi was prepared with the details, holistic with the assessments, and strategic in the approach. I would not hesitate to use them again.”
![[headshot] image of customer (for a home inspector)](https://cdn.prod.website-files.com/68c86636bce64aae0bd583b2/68c86c5aee875a9e30534dab_da918c69-68ea-42eb-8ad0-fd4f176193a5.avif)
In pharma, a plan on paper isn’t enough.
Market access and HEOR strategies must withstand payer scrutiny, shifting policies, and stakeholder resistance. That’s why Alkemi stays engaged through execution, refining evidence and messaging until your strategy resonates and delivers access.
We stand behind our work. Every project comes with our satisfaction guarantee. If something isn’t right, we’ll make it right.
Our market access and HEOR solutions are built for the unique demands of pharmaceutical companies. Alkemi delivers the tools and strategies to move faster with confidence, whether you’re defending an established product or preparing an innovation for its first payer review.
We map the entire access landscape, from payers and HTA bodies to competitive pipelines and policy shifts. This lets you see exactly where your product is vulnerable and where opportunities exist to strengthen your value story.
We uncover the precise evidence and messaging payers, HTA, guidelines and health systems need to greenlight your product. Our insights are designed to resonate with decision-makers to help you overcome hurdles to access.
In pharma, internal silos cost time and market share. Our frameworks align global, regional, and local teams around one clear market access strategy to keep your launch on track.
We build payer- and HTA-ready playbooks with pre-approved arguments, countermeasures, and trial-tested messaging. You’ll know exactly how to handle objections during price negotiations and reimbursement reviews.
Coverage is only the start. We provide rollout briefs and pull-through strategies that make it easier for prescribers, health systems, and payers to say yes, so innovative treatments reach appropriate patients without delay.
Schedule a Strategy Call with Alkemi today and get a partner who knows how pharmaceutical companies operate. We’ll help you deliver appropriate access for innovative treatments to patients worldwide.
“Access strategies executed in 90 days instead of 6-12 months, enabling us to act within the critical 30-day decision window, when access positions were still in flux and competitors were unprepared.”
“I wanted to reach out and tell you that the publication is getting GREAT reception from senior BU leadership across the company. Thank you again for your and Alkemi’s support on this project!”
“Stakeholder-validated access arguments built in 42 days, helping us retain Tier 2 formulary status and neutralize a competitor’s evidence positioning before revenue was impacted.”
“Payer value models and communication tools delivered in 45 days, giving our team immediate readiness for coverage discussions, cutting months from pricing and reimbursement timelines.”
"Really appreciate your support - as you know I rang you in a bit of a panic a few weeks ago, yet the session came across as though you’d been working on it for months. Thank you so much - this is an important event for our team, companies and clients - and you really helped make it a success. I heard 3 groups leave with ambitions to up their game - and they’re the 3 that need to do it the most - so the message landed as well."
“Patient access achieved 6 days post-approval, driving a 140% revenue increase and 90% share-price growth within 12 months through a precision-aligned market access plan.”
“Coverage positions worth $100M+ preserved after policy risks were contained and access arguments re-framed within 45 days of the initial threat.”
"When I presented the project output to our leadership, they said: 'You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward'.
“Launch readiness across 7 key markets accelerated by 6 months, improving payer perception, price confidence, and HTA alignment for sustained commercial success.”
“Cross-functional alignment reached in 21 days, uniting medical, HEOR, and commercial stakeholders around payer-critical priorities and evidence generation plans.”
“Research engagement delivered 5X more patients and 6X more clinicians than prior studies, compressing evidence-collection timelines by over 12 months.”
"Thanks to the whole team involved in staging this Advisory Council. I was fortunate to be able to attend and here the insights from the council members firsthand. The report provides an excellent summary."
“Guideline and compendia updates secured within 7 days of approval, converting scientific validation into immediate payer endorsement and market adoption.”